ClinicalTrials.gg
RecruitingNCT04430790Updated Apr 4, 2024

Doxapram Therapy in Preterm Infants (DOXA Trial)

A Phase 3 interventional study of Doxapram and Placebo in Apnea of Prematurity and Respiratory Insufficiency, sponsored by Erasmus Medical Center. Recruiting at 24 sites in 3 countries. Open to participants aged 23 Weeks to 29 Weeks. Per ClinicalTrials.gov, last updated 2024-04-04.

Sponsored by Erasmus Medical Center · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Jun 2020; still recruiting 6 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
396
Allocation
Randomized
Ages
23 Weeks to 29 Weeks
Sex
All
01

Study summary

Preterm infants often suffer from apnea of prematurity (AOP; a cessation of breathing) due to immaturity of the respiratory system. AOP can lead to oxygen shortage and a low heart rate which might harm the development of the newborn, especially the central nervous system. In order to prevent oxygen shortage, infants are treated with non-invasive respiratory support and caffeine. Despite these treatments, many preterm newborns still suffer from AOP and need invasive mechanical ventilation. Although this will result in complete resolution of AOP, invasive mechanical ventilation has the disadvantage of being a major risk of chronic lung disease and impaired neurodevelopmental outcome. Restrictive invasive ventilation is therefore advocated nowadays in preterm infants. Doxapram is a respiratory stimulant that has been administered off-label to treat AOP. Doxapram, as add-on treatment, seems to be effective in treating AOP and to prevent invasive mechanical ventilation. It is unclear if a preterm infant benefit from doxapram treatment on the longer term. This study compares doxapram to placebo and hypothesizes that doxapram will protect preterm infants from both invasive ventilation (and related lung disease) and AOP related oxygen shortage (and related impaired brain development).

Read the detailed description

The main objective of the trial is to investigate if doxapram is safe and effective in reducing the composite outcome of death and neurodevelopmental impairment/severe disability at 2 years corrected age as compared to placebo. This multicenter double blinded randomized placebo-controlled superiority trial will be conducted in multiple neonatal intensive care units in the Netherlands and Belgium, including 8 years follow-up. After written informed-consent the patients will be randomized into the doxapram treatment group or the placebo treatment group. Randomization will be stratified based on center and gestational age \< or >= 26 weeks.

The participating departments include Dutch and Belgian Neonatal Intensive care units. The units include both academic and non-academic level III and IV units that are specialized in the care for critically ill and preterm born infants. Postnatal ages of patients at doxapram start vary from directly after birth up to months for the most-preterm born infants.

Blinded continuous doxapram or placebo (glucose 5%) will be infused as long as needed. Therapy is down titrated or stopped based on the patients' condition. If endotracheal intubation is needed study drug is stopped. After extubation study drug may be restarted. Switch to gastro-enteral administration is allowed if no iv-access is needed for other reasons. Next to study drug infusion, there will be no other study-related interventions. All outcome variables are already collected as standard of care. In a subset of patients doxapram plasma levels will be determined to validate the doxapram pharmacokinetic (PK) model. Blood will only be collected during routine blood sampling, with a maximum amount of 0.6 ml. Economic and cost-effectiveness evaluation will be performed. The national protocol for preterm birth advices follow-up at 2, 5.5 and 8 years respectively, as in the current study. Additional questionnaires will be used to collect data on the quality of life of patients and their parents.

02

Conditions studied

  • Apnea of Prematurity
  • Respiratory Insufficiency

Keywords

  • Preterm infants
  • Hypoxia
  • Doxapram
03

In context

Apnea

283 studies on the registry are indexed under Apnea; 55 are open to participants now.

This study's planned enrollment of 396 is above the median of 60 across 196 interventional studies indexed under Apnea.

Browse Apnea studies →

Lead sponsor

Erasmus Medical Center is the lead sponsor of 479 studies on the registry; 182 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
23 Weeks to 29 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Admitted to the neonatal intensvie care unit (NICU) of one of the participating centres
  • Written of both parents or legal representatives
  • Gestational age at birth \< 29 weeks
  • Caffeine therapy, adequately dosed (see also under co-medication)
  • Optimal Non-invasively supported with nasal Continuous Positive Airway Pressure (CPAP) or ventilation ((S)NIPPV, NIV-NAVA, BIPAP/Duopap, SIPAP)
  • Apnea that require a medical intervention as judged by the attending physician

Exclusion criteria

Exclusion Criteria:

  • Previous use of open label doxapram
  • Use of theophylline (to replace doxapram)
  • Chromosomal defects (e.g. trisomy 13, 18, or 21)
  • Major congenital malformations that: compromise lung function (e.g. surfactant protein deficiencies, congenital diaphragmatic hernia); result in chronic ventilation (e.g. Pierre Robin sequence); increase the risk of death or adverse neurodevelopmental outcome (congenital cerebral malformations, chromosomal abnormalities);
  • Palliative care or treatment limitations because of high risk of impaired outcome.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
396 participants (estimated)

Study arms

  • Experimental
    Doxapram

    Blinded doxapram (2mg/ml, in glucose 5%) loading dose of 2.0 to 2.5 mg/kg administered in 5 to 10 minutes, followed by a continuous infusion of 0.5 - 1.0 mg/kg/hr ('www.kinderformularium.nl') as long as needed. Therapy is down titrated or stopped based on the patients' respiratory condition. If endotracheal intubation is needed study drug is stopped. After extubation study drug may be restarted. Switch to gastro-enteral administration is allowed if no iv-access is needed for other reasons.

    Drug: Doxapram

  • Placebo comparator
    Placebo

    Placebo (glucose 5%) will also be administered with a loading dose and continuous infusion (in equal amounts of fluid as in experimental arm) by intravenous or gastro-intestinal infusion. The treatment protocol will be equal to the protocol in the doxapram arm.

    Drug: Placebo

Interventions

  • Loading dose and continuous doxapram infusion.

    Also known as: Dopram

  • DrugPlacebo

    Loading dose and continuous placebo infusion.

    Also known as: Placebo (for Doxapram)

06

What researchers measure

Primary outcomes

  1. Death or severe disability

    Disability will be defined as cognitive delay, cerebral palsy, severe hearing loss, or bilateral blindness. Cognitive delay will be defined as a Mental Development Index score of less than 85 on the Bayley Scales of Infant and Toddler Development, Bayley Score of Infant Development (BSID) III scores. Cerebral palsy will be diagnosed if the child had a non-progressive motor impairment characterized by abnormal muscle tone and decreased range or control of movements. The level of gross motor function will be determined with the use of the Gross Motor Function Classification System. Audiometry will be performed to determine the presence or absence of hearing loss. Blindness will be defined as a corrected visual acuity less than 20/200

    Time frame: 2 years corrected age

Secondary outcomes

  1. Broncho pulmonary dysplasia

    Diagnosed according to the National Institute of Child Health and Human Development (NICHD) criteria

    Time frame: 36 weeks post menstrual age

  2. Death

    Death at 36 weeks post menstrual age and hospital mortality

    Time frame: until 36 weeks post menstrual age and until hospital discharge

  3. Admission period

    Length of stay at the intensive care, length of stay in hospital

    Time frame: through study completion and until discharge home, average 3 months

  4. Endotracheal intubations

    Incidence of endotracheal intubations

    Time frame: Day 3, 7, 14, and 21 after start of study medication

  5. Oxygenation days and complications

    Number of days on invasive ventilation, number of days on ventilatory support (non-invasive ventilation, CPAP, humidified high flow, low flow), number of days with supplemental oxygen, respiratory complications (airleak, pneumonia, etc), use of (rescue) corticosteroids for respiratory reasons.

    Time frame: During first hospital admittance and through study completion, average of 3 months

  6. Gastro-intestinal outcome measures

    solitary intestinal perforation, necrotizing enterocolitis \> stage 2 according to Bell, feeding problems with need for parental feeding (days with parental feeding after inclusion), body weight (gain, length), head circumference

    Time frame: During first hospital admittance and until 36 weeks post menstrual age

  7. Neurological outcome measures

    Intraventricular hemorhage(IVH) (all grades, grade III-IV, venous infarction), clinical seizures, periventricular leucomalacia (PVL) \> gr 1)

    Time frame: During first hospital admittance or at term equivalent age (37-42 weeks postmenstrual age), average 3 months

  8. Complications during neonatal period

    Incidence of late onset sepsis (culture proven or clinical suspected) and meningitis after inclusion, need for inotropes/circulatory support

    Time frame: During first hospital admittance or at term equivalent age (37-42 weeks postmenstrual age), average 3 months

  9. Retinopathy of prematurity

    Grade of retinopathy (including plus disease and need for therapy)

    Time frame: During first hospital admittance or at term equivalent age (37-42 weeks postmenstrual age), average 3 months

  10. Hearing

    Hearing test

    Time frame: At term equivalent age, 37-42 weeks postmenstrual age, average 3 months

  11. Additional long term outcomes

    Readmissions since first discharge home, weight/length/head circumference, behavioral problems (Child Behavior Checklist)

    Time frame: 2 years corrected age

  12. Parent reported outcome

    Parent reported outcome with the PARCA-R (Parent Report of Children's Abilities-Revised) questionnaire (expected mean standardised scores 100 (SD 15), higher score is better outcome)

    Time frame: 2 years corrected age

07

Study locations

18 of 24 sites recruiting
08

References and documents

Publications

  • Poppe JA, Flint RB, Smits A, Willemsen SP, Storm KK, Nuytemans DH, Onland W, Poley MJ, de Boode WP, Carkeek K, Cassart V, Cornette L, Dijk PH, Hemels MAC, Hermans I, Hutten MC, Kelen D, de Kort EHM, Kroon AA, Lefevere J, Plaskie K, Stewart B, Voeten M, van Weissenbruch MM, Williams O, Zonnenberg IA, Lacaze-Masmonteil T, Pas ABT, Reiss IKM, van Kaam AH, Allegaert K, Hutten GJ, Simons SHP. Doxapram versus placebo in preterm newborns: a study protocol for an international double blinded multicentre randomized controlled trial (DOXA-trial). Trials. 2023 Oct 10;24(1):656. doi: 10.1186/s13063-023-07683-5. PubMed 37817255 ↗

Individual participant data

Plan to share: Yes — Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: study protocol, sap and icf will be available at start of recruitment

Access criteria: data will be available on request. Requests will be discussed by the steering committee

Data sharing details ↗ · dmp.radboudumc.nl

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2020 (actual). Primary completion is estimated for May 2026, 70 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2020
First posted
Jun 12, 2020
StartActual
Jun 15, 2020
Primary completionEst.
May 1, 2026
CompletionEst.
May 1, 2034
Last update
Apr 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04430790
Collaborators
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Nederlands Neonataal Netwerk (N3), the Netherlands, Universitaire Ziekenhuizen KU Leuven, Maternal, Infant, Child and Youth Research Network (MICYRN)
Responsible party
Sinno H.P. Simons (Principal investigator, Erasmus Medical Center) — Principal investigator
First posted
Jun 12, 2020
Start date
Jun 15, 2020
Primary completion
May 1, 2026 (estimated)
Completion
May 1, 2034 (estimated)
Last update
Apr 4, 2024

Study contacts

Sinno HP Simons, MD, PhD
Contact
s.simons@erasmusmc.nl
+31641376695
Jeroen J Hutten, MD, PhD
Contact
g.j.hutten@amsterdamumc.nl
Anne Smits, MD, PhD
principal investigator · Universitair Ziekenhuis Leuven
Karel Allegaert, MD, PhD
study director · Universitair Ziekenhuis Leuven

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doxapram

Start the discussion